|
Malignant pheochromocytoma and paraganglioma
An objective response rate (including hormonal response) of 75% according to the data of 116 patients treated in various centers was observed for the use of 131I-MIBG as monotherapy with cumulative doses ranging from 3.6 to 85.9 GBq in malignant pheochromocytoma (Fig. 4). In 76% of the patients subjective improvement of symptoms, lowering of blood pressure, as well as pain relief were achieved (17). Also in malignant paraganglioma (secreting or non-secreting) objective partial remission, pain relief and improved quality of life have been described (18, 19).
|
|
|
Figure 4. Sequential anterior total body images showing progressive improvement after 131I-MIBG therapy in a patient with multiple metastases of pheochromocytoma.
|
|
|
